BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Frost & Sullivan: European HIV Diagnostics Manufacturers Need to Target Large, Undiagnosed HIV Population


2/19/2013 11:34:37 AM

LONDON – 19 February 2013 – Over 32% of HIV+ people in Europe remain undiagnosed. This large untapped pool and the development of novel nucleic acid test (NAT) and non-NAT technology based platforms offers growth potential for HIV diagnostics manufacturers.

New analysis from Frost & Sullivan (http://www.healthcare.frost.com

), Analysis of European HIV Diagnostics Market, finds that the market is estimated to expand from $797.1 million in 2012 to approximately $1,164.4 million in 2019. The research covers HIV NAT diagnostics and immunodiagnostics.

“Rising public awareness about HIV is boosting test volumes,” notes Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. “This has motivated the development of new products based on NAT and non-NAT technology platforms. The introduction of such innovative diagnostics products will be the key success factor in this market.”

Heightened interest in companion diagnostics and the adoption of automation in laboratories will reinforce market growth.

“There is a significant need for highly sensitive HIV/AIDS assays in the market, which can detect very low levels of viral RNA copies,” comments Sashidhar. “Companies are developing automated platforms to remain competitive.”

In addition, there is a greater need to recognise the correlation between virus mutations and the efficacy of various antiretroviral therapies (ARTs). Companion diagnostics are a key solution to understanding this correlation.

“Viral genotyping is a popular trend to determine mutations in the HIV genome as they mostly lead to drug resistance,” adds Sashidhar. “These demands will spur innovation, while driving market growth throughout the forecast period.”

For a variety of reasons, the level of undiagnosed population in Europe remains quite high. The biggest challenge for market participants is thus to identify and tap into this segment.

Proper education and awareness will help boost test volumes and demand for HIV diagnostic kits. Effective, low-cost offerings, together with a wide range of services including periodic kit demonstrations, can advance market prospects.

If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

Analysis of European HIV Diagnostics Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan’s related research services include: European HIV/AIDS and Hepatitis B/C Molecular Diagnostics Market, Western European In Vitro Diagnostics (IVD) Market, CEE IVD Market, and European Point of Care Testing Market. All research included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact

Anna Zanchi

Corporate Communications – Europe

P: 0039 02 46514819

E: anna.zanchi@frost.com


Read at BioSpace.com

   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->